PYC Therapeutics Ltd
ASX:PYC

Watchlist Manager
PYC Therapeutics Ltd Logo
PYC Therapeutics Ltd
ASX:PYC
Watchlist
Price: 1.2 AUD -0.83% Market Closed
Market Cap: 699.9m AUD

Wall Street
Price Targets

PYC Price Targets Summary
PYC Therapeutics Ltd

Wall Street analysts forecast PYC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PYC is 3.48 AUD with a low forecast of 2.32 AUD and a high forecast of 5.01 AUD.

Lowest
Price Target
2.32 AUD
94% Upside
Average
Price Target
3.48 AUD
190% Upside
Highest
Price Target
5.01 AUD
318% Upside
PYC Therapeutics Ltd Competitors:
Price Targets
300841
Chengdu Kanghua Biological Products Co Ltd
38% Upside
ORY
Oryzon Genomics SA
165% Upside
DVYSR
Devyser Diagnostics AB
57% Upside
VIR
Vir Biotechnology Inc
271% Upside
086900
Medy Tox Inc
27% Upside
KRYS
Krystal Biotech Inc
67% Upside
IGMS
IGM Biosciences Inc
57% Upside
PEB
Pacific Edge Ltd
7% Downside

Revenue
Forecast

Revenue Estimate
PYC Therapeutics Ltd

The compound annual growth rate of PYC Therapeutics Ltd's revenue for the next 3 years is -7%.

N/A
Past Growth
-7%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
PYC Therapeutics Ltd

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Net Income
Forecast

Net Income Estimate
PYC Therapeutics Ltd

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is PYC's stock price target?
Price Target
3.48 AUD

According to Wall Street analysts, the average 1-year price target for PYC is 3.48 AUD with a low forecast of 2.32 AUD and a high forecast of 5.01 AUD.

What is PYC Therapeutics Ltd's Revenue forecast?
Projected CAGR
-7%

The compound annual growth rate of PYC Therapeutics Ltd's revenue for the next 3 years is -7%.

Back to Top